

284	Glenmark Pharmaceuticals Limited	Ichnos Sciences SA	Wholly Owned Subsidiary	Payable	Not Applicable		1.52	1.53									
285	Glenmark Pharmaceuticals Limited	Glenmark Holding S.A. Switzerland	Wholly Owned Subsidiary	Loan	Not Applicable		53020.67	68192.12					Loan	4.5	5 years	unsecured	Business Purpose
286	Glenmark Pharmaceuticals Limited	Ichnos Sciences Biotherapeutics SA	Wholly Owned Subsidiary	Receivable	Not Applicable		6.99	6.74									
287	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria	Wholly Owned Subsidiary	Receivable/Loan	Not Applicable		429.24	435.28									
288	Glenmark Pharmaceuticals Limited	Glenmark Impex L.L.C. Russia	Wholly Owned Subsidiary	Payable	Not Applicable		283.45	304.10									
289	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals South Africa (Pty) Ltd.	Wholly Owned Subsidiary	Receivable	Not Applicable		214.58	260.62									
290	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals FZE, United Arab Emirates	Wholly Owned Subsidiary	Payable	Not Applicable		466.15	585.45									
291	Glenmark Pharmaceuticals Limited	Glenmark Generics SA, Argentina	Wholly Owned Subsidiary	Receivable	Not Applicable		0.52	3.95									
292	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Venezuela, C.A., Venezuela	Wholly Owned Subsidiary	Receivable	Not Applicable		1558.20	1558.20									
293	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Malaysia Sdn Bhd, Malaysia	Wholly Owned Subsidiary	Receivable	Not Applicable		685.86	690.56									
294	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Peru SAC, Peru	Wholly Owned Subsidiary	Receivable	Not Applicable		52.37	4.76									
295	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Europe Ltd U.K.	Wholly Owned Subsidiary	Payable	Not Applicable		1268.68	1386.81									
296	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Inc., USA	Wholly Owned Subsidiary	Receivable	Not Applicable		6226.14	0.00									
297	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Inc., USA	Wholly Owned Subsidiary	Payable	Not Applicable		0.00	2200.24									
298	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals s.r.o., Czech Republic	Wholly Owned Subsidiary	Receivable	Not Applicable		1341.17	1336.27									
299	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals SK, s.r.o., Slovak Republic	Wholly Owned Subsidiary	Payable	Not Applicable		0.01	0.01									
300	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Sp. z o.o.	Wholly Owned Subsidiary	Receivable	Not Applicable		0.01	0.01									
301	Glenmark Pharmaceuticals Limited	Int-Glenmark Distributors Sp. Z.O.O.	Wholly Owned Subsidiary	Payable	Not Applicable		0.16	0.15									
302	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand	Wholly Owned Subsidiary	Receivable/Loan	Not Applicable		33.31	30.98									
303	Glenmark Pharmaceuticals Limited	Glenmark Uruguay S.A., Uruguay	Wholly Owned Subsidiary	Payable	Not Applicable		814.66	817.44									
304	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Colombia Ltd., Colombia	Wholly Owned Subsidiary	Receivable	Not Applicable		52.85	76.98									
305	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Kenya Ltd, Kenya	Wholly Owned Subsidiary	Receivable/Loan	Not Applicable		1375.62	1665.19									
306	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Mexico, S.A. DE CV.	Wholly Owned Subsidiary	Receivable	Not Applicable		184.50	140.43									
307	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Egypt S.A.E., Egypt	Wholly Owned Subsidiary	Receivable/Loan	Not Applicable		247.74	260.62									
308	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Canada Inc.	Wholly Owned Subsidiary	Receivable	Not Applicable		316.61	209.82									
309	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals B.V., Netherlands	Wholly Owned Subsidiary	Payable	Not Applicable		0.01	0.01									
310	Glenmark Pharmaceuticals Limited	Glenmark Specialty S.A.	Wholly Owned Subsidiary	Receivable	Not Applicable		5284.85	2347.25									
311	Glenmark Pharmaceuticals Limited	Glenmark Ukraine LLC	Wholly Owned Subsidiary	Receivable	Not Applicable		229.23	179.79									
312	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Ecuador S.A.	Wholly Owned Subsidiary	Receivable	Not Applicable		95.46	71.80									
313	Glenmark Pharmaceuticals Limited	GLENMARK PHARMACEUTICALS SINGAPORE	Wholly Owned Subsidiary	Payable	Not Applicable		41.84	55.46									
314	Glenmark Pharmaceuticals Limited	ICHNOS SCIENCES INC. US	Wholly Owned Subsidiary	Receivable	Not Applicable		7.45	0.77									
315	Glenmark Pharmaceuticals Limited	PIRAMAL PHARMA LIMITED	Other Related Party	Receivable	250		12.76	0.00									
316	Glenmark Pharmaceuticals Limited	PIRAMAL PHARMA LIMITED	Other Related Party	Payable	250		0.00	26.46									
317	Glenmark Pharmaceuticals Limited	Glenmark Lifesciences Ltd	Subsidiary	Payable	10000		2526.29	3518.04									
318	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc., USA	Fellow Subsidiary	Sale of goods or services	500	230.95	219.80	451.73									
319	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Inc., USA	Fellow Subsidiary	Any other transaction	Not Applicable		40.40	0.00	0.00								
320	Glenmark Life Sciences Limited	Viso Farmaceutica S.L.U.	Fellow Subsidiary	Purchase of goods or services	35	7.46	-8.11	-2.67									
321	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Europe Ltd., U.K.	Fellow Subsidiary	Purchase of goods or services	40	1.21	-3.13	-5.64									
322	Glenmark Life Sciences Limited	Glenmark Pharmaceuticals Europe Ltd., U.K.	Fellow Subsidiary	Any other transaction	Not Applicable		0.90	0.00	0.00								
323	Glenmark Life Sciences Limited	Glenmark Farmaceutica Ltda., Brazil	Fellow Subsidiary	Purchase of goods or services	80	35.30	-24.37	-3.30									
324	Glenmark Life Sciences Limited	Glenmark Foundation	Enterprises over which significant influence exercised by key management personnel/directors	Any other transaction	70	15.50											
325	Glenmark Life Sciences Limited	Piramal Pharma Limited	Enterprises over which significant influence exercised by key management personnel/directors	Sale of goods or services	70	47.48											
326	Glenmark Life Sciences Limited	Dr. Yasir Rawjee	Managing Director & CEO	Remuneration	Not Applicable		32.19										
327	Glenmark Life Sciences Limited	Mr. Tushar Misry	Chief Financial Officer	Remuneration	Not Applicable		9.58										
328	Glenmark Life Sciences Limited	Mr. Sumantra Mitra	Executive Director	Remuneration	Not Applicable		1.57										
329	Glenmark Life Sciences Limited	Mr. Rudolf Corriea	Company Secretary & Compliance Officer	Remuneration	Not Applicable		1.12										
330	Glenmark Life Sciences Limited	Mr. Vinod Nalik	Executive Director	Remuneration	Not Applicable		12.88										
331	Glenmark Life Sciences Limited	Mr. Bhavesh Pujara	Chief Financial Officer	Remuneration	Not Applicable		1.50										
332	Glenmark Life Sciences Limited	Mrs. Manju Agarwal	Non-executive Director	Any other transaction	Not Applicable		0.60										
333	Glenmark Life Sciences Limited	Mr. T. Leaswar	Non-executive Director	Any other transaction	Not Applicable		0.50										
334	Glenmark Life Sciences Limited	Ms. Gita Nayyar	Non-executive Director	Any other transaction	Not Applicable		0.70										
335	Glenmark Life Sciences Limited	Mr. Srihar Gorthi	Non-executive Director	Any other transaction	Not Applicable		1.00										
336	Glenmark Pharmaceuticals Limited	Glenmark Impex L.L.C	Wholly Owned Subsidiary	Investment	Not Applicable		1,435.61	1,435.61									
337	Glenmark Pharmaceuticals Limited	Glenmark Philippines Inc.	Wholly Owned Subsidiary	Investment	Not Applicable		116.70	116.70									
338	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Nigeria) Ltd	Wholly Owned Subsidiary	Investment	Not Applicable		208.97	208.97									
339	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Malaysia Sdn Bhd	Wholly Owned Subsidiary	Investment	Not Applicable		97.72	97.72									
340	Glenmark Pharmaceuticals Limited	Glenmark Holding S.A.	Wholly Owned Subsidiary	Investment	Not Applicable		94,663.83	94,663.83									
341	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Australia) Pty Ltd	Wholly Owned Subsidiary	Investment	Not Applicable		101.72	101.72									
342	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Egypt S.A.E.	Wholly Owned Subsidiary	Investment	Not Applicable		421.74	421.74									
343	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals FZE	Wholly Owned Subsidiary	Investment	Not Applicable		12.92	12.92									
344	Glenmark Pharmaceuticals Limited	Glenmark Dominicana SRL	Wholly Owned Subsidiary	Investment	Not Applicable		0.19	0.19									
345	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Kenya Ltd	Wholly Owned Subsidiary	Investment	Not Applicable		97.18	97.18									
346	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Colombia SAS, Colombia	Wholly Owned Subsidiary	Investment	Not Applicable		545.89	577.45									
347	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Peru SAC	Wholly Owned Subsidiary	Investment	Not Applicable		827.79	827.79									
348	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Mexico, S.A. DE CV.	Wholly Owned Subsidiary	Investment	Not Applicable		1,695.29	1,695.29									
349	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Europe Ltd., U.K.	Wholly Owned Subsidiary	Investment	Not Applicable		578.23	578.23									
350	Glenmark Pharmaceuticals Limited	Glenmark South Africa (pty) Ltd	Wholly Owned Subsidiary	Investment	Not Applicable		1,044.20	1,044.20									
351	Glenmark Pharmaceuticals Limited	Glenmark Uruguay S.A.	Wholly Owned Subsidiary	Investment	Not Applicable		774.53	774.53									
352	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Thailand) Co. Ltd	Wholly Owned Subsidiary	Investment	Not Applicable		3.72	3.72									
353	Glenmark Pharmaceuticals Limited	Glenmark-Pharmaceuticals Ecuador S.A.	Wholly Owned Subsidiary	Investment	Not Applicable		189.46	189.46									
354	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Singapore Pte. Ltd.	Wholly Owned Subsidiary	Investment	Not Applicable		32.73	32.73									
355	Glenmark Pharmaceuticals Limited	Glenmark Life Sciences Limited	Wholly Owned Subsidiary	Investment	Not Applicable		14.41	14.41									
356	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Loan given	Not Applicable		2782.06	2,559.07	932.22								

357	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Investment	Not Applicable	6,825.93	23,395.00	30,220.93											
358	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Interest income	Not Applicable	61.11													
359	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Other Income	Not Applicable	579.85													
360	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Receivable	Not Applicable		1,836.27	113.23											
361	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Investment	Not Applicable		19.84	19.84											
362	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Payable	Not Applicable		1.34	1.54											
363	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Payable	Not Applicable		2.31	2.62											
364	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Expense incurred	Not Applicable	2.60													
365	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Other Income	Not Applicable	1361.33													
366	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Receivable	Not Applicable		765.83	1,340.15											
367	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Payable	Not Applicable		0.60	3.97											
368	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Expense reimbursed	Not Applicable	3.29													
369	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan given	Not Applicable		-	33.19											
370	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan given	Not Applicable	32.00													
371	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan repaid	Not Applicable	1.24													
372	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	Interest Income	Not Applicable	0.32													

1 All Related Party Transactions entered during the period were in ordinary course of the business and on arm's length basis.

2 Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.

3 Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.

4 Balances have been aggregated entity wise for all type of transactions and shown as net receivable/payable

5 As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.

6 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors, as applicable, for financial year 2022-23.

7 All transactions in foreign currency, wherever applicable, have been converted and disclosed in INR.

8 Difference in opening and closing balances is on account of exchange rate fluctuation.

9 All figures in this disclosure are rounded off up to two decimals.